The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC EBITDA Margin
EBITDA as a percentage of revenue.
The Chemours CompanyNYSE: CC
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to -26.0%
EBITDA Margin was -26.0% in Q2 FY2026, down 19.6 pp from a year earlier. On a trailing-twelve-month basis it was -2.9%, down 8.3 pp year over year. Over 3 fiscal years it narrowed by 11.8 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 12.3% for the fiscal year ending Dec 2026, up from 5.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -26.0%-35.0 pp QoQ
- Last fiscal yearDec 2025
- 5.7%-6.3 pp YoY
- LTMJun 2026
- -2.9%-8.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -19.6 pp | -0.4 pp | +19.2 pp |
| 1 year | -6.3 pp | +6.6 pp | +12.8 pp |
| 3 years | -11.8 pp | +9.5 pp | +21.2 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 5.7%
- Year-over-year change
- -6.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.7% | -6.3pp |
| FY2024 | 2024-12-31 | 12.0% | +8.7pp |
| FY2023 | 2023-12-31 | 3.2% | -14.3pp |
| FY2022 | 2022-12-31 | 17.5% | -1.1pp |
| FY2021 | 2021-12-31 | 18.6% | — |
EBITDA Margin vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 EBITDA Margin of -2.9% is the 17th highest of the 19 companies compared; the peer median is 15.1%.
- Its year-over-year change of -8.3 pp is the 17th highest of 19, against a peer median of +0.5 pp.
- Over three fiscal years its change of -11.8 pp compares with a peer median of -3.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 37.9% | -0.2 pp | +6.3 pp | |
| LTM Jun 2026 | 20.6% | +47.2 pp | -49.2 pp | |
| LTM Jun 2026 | 19.1% | -0.9 pp | +5.9 pp | |
| LTM Jun 2026 | 19.0% | -2.3 pp | +9.0 pp | |
| LTM Mar 2026 | 18.5% | +2.5 pp | -6.6 pp | |
| LTM Sep 2026 | 17.8% | +2.4 pp | +3.3 pp | |
| LTM Jun 2026 | 17.7% | +0.9 pp | -0.7 pp | |
| LTM Jun 2026 | 16.9% | +0.1 pp | +4.8 pp | |
| LTM Aug 2026 | 15.2% | +1.3 pp | +2.1 pp | |
| LTM Jun 2026 | 14.9% | +8.1 pp | +8.0 pp | |
| LTM Sep 2026 | 13.4% | -5.7 pp | -6.9 pp | |
| LTM Sep 2026 | 11.7% | +10.2 pp | -8.6 pp | |
| LTM Sep 2026 | 11.5% | +3.0 pp | +1.5 pp | |
| LTM Mar 2026 | 7.8% | -3.3 pp | -6.3 pp | |
| LTM Sep 2026 | 6.0% | +1.8 pp | -28.8 pp | |
| LTM Sep 2026 | 5.9% | -5.2 pp | -29.1 pp | |
| LTM Jun 2026 | -2.9% | -8.3 pp | -11.8 pp | |
| LTM Mar 2026 | -38.2% | -39.3 pp | -47.3 pp | |
| LTM Jun 2026 | -39.6% | -63.9 pp | -75.9 pp | |
| Peer median (excluding CC) | 15.1% | +0.5 pp | -3.5 pp | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.35B | 6.83B | 6.08B | 5.78B | 5.81B |
| Cost of Revenue | 4.96B | 5.22B | 4.77B | 4.63B | 4.91B |
| Gross Profit | 1.38B | 1.62B | 1.31B | 1.15B | 902M |
| Gross Margin | 21.8% | 23.7% | 21.5% | 19.9% | 15.5% |
| Research & Development | 107M | 118M | 108M | 109M | 108M |
| Selling, General & Admin | 592M | 710M | 1.29B | 585M | 799M |
| Operating Expenses | 707M | 830M | 1.43B | 708M | 907M |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| EBITDA | 1.18B | 1.2B | 197M | 692M | 332M |
| EBITDA Margin | 18.6% | 17.5% | 3.2% | 12.0% | 5.7% |
| Operating Income | 674M | 786M | (123M) | 443M | (5M) |
| Operating Margin | 10.6% | 11.5% | -2.0% | 7.7% | -0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 185M | 163M | 208M | 264M | 269M |
| Other Income / Expenses | 2M | (45M) | (195M) | (316M) | (272M) |
| Income Before Tax | 676M | 741M | (318M) | 127M | (277M) |
| Pre-Tax Margin | 10.7% | 10.8% | -5.2% | 2.2% | -4.8% |
| Income Tax Expense | 68M | 163M | (81M) | 41M | 109M |
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Net Margin | 9.6% | 8.5% | -3.9% | 1.5% | -6.6% |
| EPS (Basic) | 3.69 | 3.72 | (1.60) | 0.58 | (2.57) |
| EPS (Diluted) | 3.60 | 3.65 | (1.60) | 0.57 | (2.56) |
| Weighted Avg Shares | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M |
| Weighted Avg Shares (Diluted) | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.